Skip to content

Mhc Class I Deficiency 3 C5935618

Published: July 22, 2026Updated: August 20, 2026

A rare inherited immune disorder impairing cellular immune function, resulting in susceptibility to viral infections. Bone marrow transplantation may be considered in severe cases.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
D89.9
ICD-11
3A00.0
Body system
immunologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Severe mucocutaneous herpesvirus infection

!

Granulomatous skin lesions

Generalized symptoms

(immunologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Recurrent upper respiratory tract infections

(immunologic)

Chronic sinusitis

(immunologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Combination drug regimen with regular assessment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Immunoglobulin Replacement

Regular immunoglobulin therapy providing broad-spectrum antibody coverage to compensate for immune dysregulation affecting antigen presentation pathways.

medication
3

Antimicrobial Prophylaxis Protocol

Customized prophylactic antibiotic regimen based on individual infection history and susceptibility testing, typically including coverage for respiratory and skin pathogens.

medication

Additional treatment options

Stem Cell Evaluation

Hematopoietic stem cell transplantation assessment for eligible patients, as this represents the only curative approach for severe immunodeficiency presentations.

procedure

Environmental Modification

Home modifications including air filtration systems, HEPA filters, and dedicated sick room to reduce environmental pathogen load for immunocompromised individuals.

lifestyle

Infection Surveillance Program

Regular surveillance cultures and imaging to detect subclinical infections before symptom onset, particularly respiratory and sinus involvement.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Mhc Class I Deficiency 3 C5935618?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Mhc Class I Deficiency 3 C5935618. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy